       Document 0059
 DOCN  M9590059
 TI    Protection of SJL/J mice from demyelinating disease mediated by
       Theiler's murine encephalomyelitis virus.
 DT    9509
 AU    Kurtz CI; Sun XM; Fujinami RS; Department of Neurology, University of
       Utah School of Medicine,; Salt Lake City 84132, USA.
 SO    Microb Pathog. 1995 Jan;18(1):11-27. Unique Identifier : AIDSLINE
       MED/95302931
 AB    Intracerebral infection with the DA strain of Theiler's murine
       encephalomyelitis virus induces a chronic demyelinating disease in SJL/J
       mice. Intraperitoneal inoculation with either the wild-type DA virus or
       an attenuated variant virus of DA, H7A6-2, results in protection from
       development of chronic demyelinating disease. Protective anti-viral
       immune responses result in reduced viral titers and decreased
       inflammation in the central nervous system within the first week
       following intracerebral challenge with virus. Development of protective
       immunity requires the presence of B cells and CD4+ T cells but does not
       require CD8+ T cells. High titers of serum anti-viral IgG and
       neutralizing antibodies are induced following the intraperitoneal
       inoculation with the DA virus or H7A6-2 virus prior to challenge. While
       protection could not be transferred with immune serum from DA
       virus-infected mice or neutralizing monoclonal antibodies, protection
       was correlated with increased numbers of DA virus-specific plasma cells
       in the central nervous system within the first week following
       intracerebral challenge. Protected mice also had enhanced levels of
       anti-DA virus IgG and neutralizing antibodies in the cerebral spinal
       fluid by 1 week following intracerebral challenge with DA virus. Thus,
       we conclude that vaccination with live virus results in protection from
       chronic demyelinating disease by inducing immune responses which are
       manifested in the central nervous system and rapidly clear infection
       after intracerebral challenge with DA virus.
 DE    Animal  B-Lymphocytes/IMMUNOLOGY  Brain/IMMUNOLOGY  Cardiovirus
       Infections/*PREVENTION & CONTROL  Central Nervous
       System/*IMMUNOLOGY/PATHOLOGY/VIROLOGY  CD4-Positive
       T-Lymphocytes/IMMUNOLOGY  CD8-Positive T-Lymphocytes/IMMUNOLOGY
       Demyelinating Diseases/*PREVENTION & CONTROL  Encephalomyelitis Virus,
       Murine/*IMMUNOLOGY  Female  Immunity, Cellular/IMMUNOLOGY  Lymphocyte
       Depletion  Mice  Mice, Inbred Strains  Neutralization Tests  Plasma
       Cells  Spinal Cord/IMMUNOLOGY  Support, Non-U.S. Gov't  Support, U.S.
       Gov't, P.H.S.  Vaccines, Attenuated/THERAPEUTIC USE  Viral
       Vaccines/*THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

